首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index.
【24h】

Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index.

机译:使用基于肌酐和半胱氨酸蛋白酶抑制剂C的估算方程对CKD进行差分估算,并按体重指数分类。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGOUND: Adiposity is associated with cystatin C. Cystatin C-based glomerular filtration rate (GFR) equations may result in overestimation of chronic kidney disease (CKD) prevalence at greater body mass index (BMI) levels. STUDY DESIGN: Cross-sectional. SETTING & PARTICIPANTS: 6,709 US adult Third National Health and Nutrition Examination Survey participants. FACTOR: BMI. OUTCOME: Absolute percentage of difference in prevalence of stage 3 or 4 CKD between creatinine- and cystatin C-based estimating equations by level of BMI. MEASUREMENTS: Normal weight, overweight, and obesity were defined as BMI of 18.5 to less than 25.0, 25 to less than 30.0, and 30 kg/m(2) or greater, respectively. Stage 3 or 4 CKD (estimated glomerular filtration rate [eGFR], 15 to 59 mL/min/1.73 m(2)) was defined using the 4-variable creatinine-based Modification of Diet in Renal Disease Study equation (eGFR(MDRD)); cystatin C level, age, sex, and race equation (eGFR(CysC,age,sex,race)); cystatin C-only equation (eGFR(CysC)); cystatin C level of 1.12 mg/L or greater (increased cystatin C); and an equation incorporating serum creatinine level, cystatin C level, age, sex, and race (eGFR(Cr,CysC,age,sex,race)). RESULTS: Differences in stage 3 or 4 CKD prevalence estimates between eGFR(CysC,age,sex,race), eGFR(CysC), and increased cystatin C, separately, and eGFR(MDRD) were greater at higher BMI levels. Specifically, compared with estimates derived using eGFR(MDRD) for normal-weight, overweight, and obese participants, estimated prevalences of stage 3 or 4 CKD were 2.1%, 3.0%, and 6.5% greater when estimated by using eGFR(CysC,age,sex,race) (P trend = 0.005); 0.1%, 0.6%, and 2.2% greater for eGFR(CysC) (P trend = 0.03); 2.9%, 5.2%, and 9.5% greater for increased cystatin C (P trend < 0.001); and -0.1%, -0.4%, and 0.0% greater for eGFR(Cr,CysC,age,sex,race), respectively (P trend = 0.7). LIMITATIONS: No gold-standard measure of GFR was available. CONCLUSIONS: BMI may influence the estimated prevalence of stage 3 or 4 CKD when cystatin C-based equations are used.
机译:背景:肥胖与胱抑素C相关。基于胱抑素C的肾小球滤过率(GFR)方程可能会导致在较高的体重指数(BMI)水平上高估慢性肾脏病(CKD)患病率。研究设计:横截面。参加者和参与者:6,709名美国成人第三次全国健康和营养检查调查参与者。因素:BMI。结果:基于BMI水平的基于肌酐和胱抑素C的估计方程在3或4期CKD患病率中的绝对百分比差异。测量:正常体重,超重和肥胖定义为BMI分别为18.5至小于25.0、25至小于30.0和30 kg / m(2)或更高。肾脏疾病研究方程式(eGFR(MDRD))中基于肌酐的基于4变量的修改定义了第3或第4阶段CKD(估计肾小球滤过率[eGFR],15至59 mL / min / 1.73 m(2)) );胱抑素C水平,年龄,性别和种族方程式(eGFR(CysC,年龄,性别,种族));仅胱抑素C方程(eGFR(CysC));半胱氨酸蛋白酶抑制剂C水平为1.12 mg / L或更高(半胱氨酸蛋白酶抑制剂C增加);和包含血清肌酐水平,胱抑素C水平,年龄,性别和种族的方程(eGFR(Cr,CysC,年龄,性别,种族))。结果:在较高的BMI水平下,eGFR(CysC,年龄,性别,种族),eGFR(CysC)和胱抑素C分别升高和eGFR(MDRD)在3期或4期CKD患病率估计值之间的差异更大。具体而言,与使用eGFR(MDRD)得出的正常体重,超重和肥胖参与者的估计值相比,使用eGFR(CysC,age)估计的3或4期CKD患病率分别高2.1%,3.0%和6.5%。 ,性别,种族)(P趋势= 0.005); eGFR(CysC)分别增加0.1%,0.6%和2.2%(P趋势= 0.03);胱抑素C增加的幅度分别为2.9%,5.2%和9.5%(P趋势<0.001); eGFR(Cr,CysC,年龄,性别,种族)分别增加-0.1%,-0.4%和0.0%(P趋势= 0.7)。局限性:没有可用的黄金标准的GFR。结论:当使用基于胱抑素C的方程时,BMI可能会影响3或4期CKD的估计患病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号